Sign in

    Trung Ho

    Research Analyst at UBS

    No public records or analyst profiles have been found for Trung Ho as an analyst at UBS. There is no evidence of a UBS analyst by this name with data on company coverage, performance track record, career timeline, or professional credentials. Without a confirmed identity, job title, or career details from LinkedIn or notable financial research platforms, a verified professional profile cannot be provided.

    Trung Ho's questions to INSMED (INSM) leadership

    Trung Ho's questions to INSMED (INSM) leadership • Q2 2025

    Question

    Speaking on behalf of Trung Ho, an analyst asked about the potential read-through from the Birch (CRS) trial to the CEDAR (HS) trial and sought clarification on the endpoint for the CEDAR futility analysis.

    Answer

    CEO William Lewis expressed higher confidence in the Birch trial due to the biological similarity between CRS and bronchiectasis, calling HS a 'trickier disease' with more uncertainty. CMO Martina Flammer clarified that the CEDAR futility analysis will focus specifically on the primary endpoint: the percentage change in abscess and nodule count at week 16.

    Ask Fintool Equity Research AI